Expanded endothelial progenitor cells mitigate lung injury in septic mice

• Published in: Stem cell research & therapy 2015-11, Vol.6 (1), p.230-230, Article 230
• Main Authors: Güldner, Andreas, Maron-Gutierrez, Tatiana, Abreu, Soraia Carvalho, Xisto, Debora Gonçalves, Senegaglia, Alexandra Cristina, Barcelos, Patty Rose da Silva, Silva, Johnatas Dutra, Brofman, Paulo, de Abreu, Marcelo Gama, Rocco, Patricia Rieken Macedo
• Format: Article
• Language: English
• Subjects: AC133 Antigen; Animals; Antigens, CD; Cell Proliferation; Comparative analysis; Endothelial Progenitor Cells; Endothelium; Fetal Blood; Glycoproteins; Humans; Infection; Inflammation Mediators - metabolism; Intercellular Signaling Peptides and Proteins - metabolism; Interleukins; Lung - metabolism; Lung - pathology; Lung Injury - etiology; Lung Injury - pathology; Lung Injury - therapy; Mice; Mice, Inbred BALB C; Peptides; Phenotype; Platelet-derived growth factor; Respiratory Function Tests; Sepsis - complications; Short Report; Stem cells; Vascular endothelial growth factor
• ISSN: 1757-6512; 1757-6512
• DOI: 10.1186/s13287-015-0226-7

Endothelial progenitor cells (EPCs) improve survival and reduce organ failure in cecal ligation and puncture-induced sepsis; however, expanded EPCs may represent an even better approach for vascular repair. To date, no study has compared the effects of non-expanded EPCs (EPC-NEXP) with those of expanded EPCs (EPC-EXP) and mesenchymal stromal cells of human (MSC-HUMAN) and mouse (MSC-MICE) origin in experimental sepsis. One day after cecal ligation and puncture sepsis induction, BALB/c mice were randomized to receive saline, EPC-EXP, EPC-NEXP, MSC-HUMAN or MSC-MICE (1 × 10(5)) intravenously. EPC-EXP, EPC-NEXP, MSC-HUMAN, and MSC-MICE displayed differences in phenotypic characterization. On days 1 and 3, cecal ligation and puncture mice showed decreased survival rate, and increased elastance, diffuse alveolar damage, and levels of interleukin (IL)-1β, IL-6, IL-10, tumor necrosis factor-α, vascular endothelial growth factor, and platelet-derived growth factor in lung tissue. EPC-EXP and MSC-HUMAN had reduced elastance, diffuse alveolar damage, and platelet-derived growth factor compared to no-cell treatment. Tumor necrosis factor-α levels decreased in the EPC-EXP, MSC-HUMAN, and MSC-MICE groups. IL-1β levels decreased in the EPC-EXP group, while IL-10 decreased in the MSC-MICE. IL-6 levels decreased both in the EPC-EXP and MSC-MICE groups. Vascular endothelial growth factor levels were reduced regardless of therapy. In conclusion, EPC-EXP and MSC-HUMAN yielded better lung function and reduced histologic damage in septic mice.